264 related articles for article (PubMed ID: 25265656)
1. [The importance of cytokine profile characteristics for evaluating the therapeutic effectiveness of monoclonal antibodies against IL-6 receptors in patients with rheumatoid arthritis].
Avdeev AS; Novikov AA; Aleksandrova EN; Panasiuk EIu; Nasonov EL
Klin Med (Mosk); 2014; 92(1):28-34. PubMed ID: 25265656
[TBL] [Abstract][Full Text] [Related]
2. [The immunologic predictors of effect of anti-B-cell therapy under rheumatoid arthritis].
Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Nasonov EL
Klin Lab Diagn; 2014 Mar; (3):48-52. PubMed ID: 25080789
[TBL] [Abstract][Full Text] [Related]
3. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
4. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
Smolen JS; Aletaha D
Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt.
Romão VC; Santos MJ; Polido-Pereira J; Duarte C; Nero P; Miguel C; Costa JA; Bernardes M; Pimentel-Santos FM; Barcelos F; Costa L; Melo Gomes JA; Pereira da Silva JA; Cunha Branco J; Canas da Silva J; Pereira da Silva JA; Fonseca JE; Canhão H
Biomed Res Int; 2015; 2015():279890. PubMed ID: 26000286
[TBL] [Abstract][Full Text] [Related]
7. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis.
Levi M; Grange S; Frey N
J Clin Pharmacol; 2013 Feb; 53(2):151-9. PubMed ID: 23436260
[TBL] [Abstract][Full Text] [Related]
8. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
Nasonov EL
Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
[TBL] [Abstract][Full Text] [Related]
9. Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade.
Gualtierotti R; Ingegnoli F; Griffini S; Grovetti E; Meroni PL; Cugno M
Clin Exp Rheumatol; 2016; 34(3):451-8. PubMed ID: 27086948
[TBL] [Abstract][Full Text] [Related]
10. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
[TBL] [Abstract][Full Text] [Related]
11. Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis.
Kasama T; Isojima S; Umemura M; Tsukamoto H; Tokunaga T; Furuya H; Yanai R; Takahashi R; Nakamura M; Inagaki K
Rheumatol Int; 2014 Mar; 34(3):429-33. PubMed ID: 23670804
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment Prediction of Individual Rheumatoid Arthritis Patients' Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers.
Uno K; Yoshizaki K; Iwahashi M; Yamana J; Yamana S; Tanigawa M; Yagi K
PLoS One; 2015; 10(7):e0132055. PubMed ID: 26176225
[TBL] [Abstract][Full Text] [Related]
13. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
[TBL] [Abstract][Full Text] [Related]
14. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis.
Hitchon CA; Alex P; Erdile LB; Frank MB; Dozmorov I; Tang Y; Wong K; Centola M; El-Gabalawy HS
J Rheumatol; 2004 Dec; 31(12):2336-46. PubMed ID: 15570632
[TBL] [Abstract][Full Text] [Related]
15. [Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms].
Zhu HL; DU Q; Chen WL; Zuo XX; Li QZ; Liu SJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Aug; 51(4):716-722. PubMed ID: 31420628
[TBL] [Abstract][Full Text] [Related]
16. Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer.
Kumari N; Agrawal U; Mishra AK; Kumar A; Vasudeva P; Mohanty NK; Saxena S
Tumour Biol; 2017 Apr; 39(4):1010428317697552. PubMed ID: 28378639
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy.
Snir A; Kessel A; Haj T; Rosner I; Slobodin G; Toubi E
Clin Exp Rheumatol; 2011; 29(4):697-700. PubMed ID: 21813064
[TBL] [Abstract][Full Text] [Related]
18. Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy.
Wright HL; Bucknall RC; Moots RJ; Edwards SW
Rheumatology (Oxford); 2012 Mar; 51(3):451-9. PubMed ID: 22179732
[TBL] [Abstract][Full Text] [Related]
19. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
[TBL] [Abstract][Full Text] [Related]
20. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Origuchi T; Ueki Y; Migita K; Mizokami A; Aoyagi K; Eguchi K
Mod Rheumatol; 2011 Aug; 21(4):370-4. PubMed ID: 21240618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
